Briefings in Bioinformatics · 2022 · 142 citations · 43 references
PharmacyPharmacologyComputational BiologyDrug DesignDrug DiscoveryComputational Drug DiscoveryDeep LearningDrug Knowledge RepresentationMolecular DockingPharmaceutical Knowledge RepresentationBenchmark DatasetsCross-validationDrug - Disease Association PredictionDrug Association ModelingDrug-disease NetworksHeterogeneous NetworksK-fold Cross-validationNetwork-based Drug Discovery
Drug repositioning (DR) is a promising strategy to discover new indicators of approved drugs with artificial intelligence techniques, thus improving traditional drug discovery and development. However, most of DR computational methods fall short of taking into account the non-Euclidean nature of biomedical network data. To overcome this problem, a deep learning framework, namely DDAGDL, is proposed to predict drug-drug associations (DDAs) by using geometric deep learning (GDL) over heterogeneous information network (HIN). Incorporating complex biological information into the topological structure of HIN, DDAGDL effectively learns the smoothed representations of drugs and diseases with an attention mechanism. Experiment results demonstrate the superior performance of DDAGDL on three real-world datasets under 10-fold cross-validation when compared with state-of-the-art DR methods in terms of several evaluation metrics. Our case studies and molecular docking experiments indicate that DDAGDL is a promising DR tool that gains new insights into exploiting the geometric prior knowledge for improved efficacy.
43
Helen M. Berman · Nucleic Acids Research · 2000 · 39.8K citations
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart, Yannick Djoumbou-Feunang, An Chi Guo et al. · Nucleic Acids Research · 2017 · 8.8K citations · Full text